A patient with septic shock is being treated with norepinephrine. Which is the primary goal of this therapy?

GMCH Nursing Officer-2025

Pharmacology

Medium

Appeared in: GMCH Nursing Officer-2025

Explanation

Septic shock is a form of distributive shock characterized by widespread vasodilation, leading to a critical drop in systemic vascular resistance (SVR) and mean arterial pressure (MAP).
Norepinephrine is the first-line vasopressor for septic shock, as recommended by clinical guidelines.
Its primary action is stimulating alpha-1 (α₁) adrenergic receptors in the blood vessels, which causes potent vasoconstriction.
This vasoconstriction directly increases SVR, which in turn raises the MAP, the primary therapeutic goal to restore blood flow and oxygen delivery to vital organs.

Option B: Norepinephrine has beta-1 (β₁) adrenergic effects that are chronotropic, meaning they typically increase, not reduce, the heart rate.
Option C: By increasing heart rate, contractility (inotropy), and afterload (SVR), norepinephrine increases the heart's workload and thus increases, rather than decreases, myocardial oxygen demand.
Option D: Improved urine output is a desired secondary outcome, not the primary goal. It is an indirect result of increased renal perfusion pressure from a higher MAP, not a direct diuretic or renal-specific action of the drug.

Visual 1: Diagram: Illustrating the mechanism of norepinephrine on alpha-1 receptors of vascular smooth muscle, leading to vasoconstriction and increased SVR.
Visual 2: Flowchart: Showing the progression from sepsis to septic shock and the role of vasopressors like norepinephrine in the management algorithm.

Clinical Relevance

Nursing practice connection: Prioritize focused assessment, early escalation, and real-time monitoring when managing Pharmacological management of septic shock using vasopressors in acute care settings.
Nurses must administer norepinephrine via a central venous catheter. Extravasation (leakage into surrounding tissue) can cause severe tissue necrosis due to its potent vasoconstrictive effects.
Continuous hemodynamic monitoring, especially with an arterial line for real-time MAP measurement, is crucial for titrating the infusion to the target MAP (typically greater than 65 mmHg) while avoiding complications of excessive vasoconstriction.
What if? If a patient on norepinephrine develops severe tachycardia (e.g., heart rate greater than 140 bpm), the nurse should anticipate the potential addition of a second agent like vasopressin to reduce the norepinephrine dose, or in some cases, a cardioselective beta-blocker if hemodynamically tolerated, to control the heart rate.

How to Approach the Question

First, identify the key elements of the question: the patient has 'septic shock' and is receiving 'norepinephrine'. The question asks for the 'primary goal'.
Recall the core pathophysiology of septic shock: it is a distributive shock defined by massive vasodilation, which causes low systemic vascular resistance (SVR) and profound hypotension (low MAP).
Next, recall the primary drug class and action of norepinephrine. It is a 'vasopressor,' meaning it constricts blood vessels.
Connect the problem (vasodilation) with the solution (vasopressor). The goal is to counteract the vasodilation.
Evaluate the options based on this connection. Constricting blood vessels increases resistance (SVR) and pressure (MAP), directly matching the primary goal of treating septic shock.
Eliminate other options by considering the drug's side effects (it increases heart rate and oxygen demand) and distinguishing primary goals from secondary outcomes (urine output is an indirect result).

Concept Tested & Keywords

QzHPenhbTDlfe7vPPW_qa